Biopharma in China
How the Pharmaceutical and Biopharmaceutical Industry Works
In the China Biopharmaceutical Industry Report, the analysts provide insights into recent market developments and current conditions and highlight the industry's opportunities and challenges.
With its tremendous growth spurt, China's pharmaceutical and biopharmaceutical industry offers excellent opportunities for the global equipment industry.
Even though the country also wants to reduce its dependence on foreign suppliers in this segment in the future, the industry is investing heavily in R&D, technology, and training. In 2020, for example, the cumulative value-added of the Chinese pharmaceutical sector rose by 5.9% year-on-year, while capital expenditure on property, plant, and equipment even recorded an increase of more than 28%.
The rapid growth spurt has made the sector one of China's leading industries. According to the National Bureau of Statistics, biopharmaceutical production is growing faster than the production of traditional Chinese medicine or conventional drugs. Studies and analyses by M2 Consulting in cooperation with PharmaTEC China indicate an average growth of about 15%. The enormous development potential of the biopharmaceutical segment will therefore continue to attract further investment in the future.
In a 134-page "2020 China Biopharmaceutical Industry Report", the analysts provide insights into recent market developments and current conditions and highlight the industry's opportunities and challenges. The report also looks at approval processes, product design, and technological developments and their impact on manufacturing and quality control.
The provider of this whitepaper